Educational research platform

Before you begin

Welcome to Peptide Relay

Explore source-linked research, practical tools, and Community Intelligence with evidence, interpretation, and personal experience kept clearly separated.

Please confirm
Choose how you enter RelayYou can change your mind and create a workspace later.

No account is required for the Research Library, Learn, Compare, Stack Explorer, Community, or Tools. A free workspace is only required for private features such as My Relay, Protocol Tracker, saved work, following compounds, and managing Community Experiences.

Peptide Relay status

Public Alpha

v0.9.0

Building Relay with the community.

Relay is now feature-complete and has entered its first Public Alpha.

From this point forward, improvements are driven by real-world usage, community feedback, analytics, and research rather than internal feature planning.

Thank you for helping shape Relay.

What's NewWhat shipped in the current release
v0.9.0 — Public AlphaJuly 2026

Research Library

Thirty-five source-traceable compound and blend profiles with plain-English summaries, detailed science, evidence context, timelines, and references.

Learn

Peptide 101 and seven cornerstone guides for reading studies, mechanisms, evidence strength, personal experiences, and research uncertainty.

Compare

Side-by-side research context with shared, different, and unknown states—without inventing head-to-head conclusions.

Stack Explorer

Multi-compound pathway and evidence analysis with exact-combination limits and unanswered questions kept visible.

Community Experiences

Anonymous structured Experience Reports, separate story consent, verified follow-ups, moderation, and privacy-thresholded Community Intelligence.

Protocol Tracker

Private schedules, administrations, reflections, measurements, inventory, imports, lifecycle controls, and reconstitution support.

Reconstitution Hub

Single-compound and blend calculations, visual syringe and vial interpretation, reference marks, and private saved workspaces.

Relay-wide Search

One alias-aware search experience across public research and signed-in workspace destinations.

Mobile Optimization

Reliable touch selection, tighter information density, responsive tables and tabs, and mobile-first workflow refinement.

Motion System

One restrained motion language that explains state changes and respects reduced-motion preferences.

Platform Improvements

Database contract auditing, private-route indexing boundaries, public-route smoke tests, clearer recovery messages, and stronger protection against false-success writes.

RoadmapDirection without promised timelines

Roadmap items describe current direction. Public Alpha evidence may change their order or scope.

Now
  • Community growth
  • Bug fixes
  • UX improvements
  • Content expansion
Next
  • Relay+ features
  • Additional research tools
  • Expanded compound library
Future
  • Relay AI
  • Native iPhone app (planned)
  • Native Android app (planned)
Known IssuesMeaningful issues users may encounter
No known critical issues at this time.

Newly confirmed issues will appear here when they meaningfully affect the public experience.

FeedbackHelp improve the next release

Found a bug?Have a suggestion?

Submit feedback to help improve Relay
Version HistoryPublic releases and milestones
v0.9.0

Public Alpha

The first feature-complete public release candidate for Peptide Relay.

Released July 2026

Last updated July 2026 · Updated with every public release.

Peptide RelayResearch, relayed clearly.

Search Relay

Find research or go anywhere.

⌘/Ctrl K
Quick destinations
↑↓ navigate Enter open
Sign in

Simple first. Deeper when you want it.

See how the evidence connects.

Understand why compounds are viewed together, where their biology overlaps, what current evidence supports, and what research still cannot answer.

2 of 6 selected

Start with two compounds, then add more when the question requires it.

Triple receptor agonist
Growth hormone–releasing hormone (GHRH) analog

60-second understanding

Reta + Tesa

What the current evidence shows together
Why this stack is interesting

Retatrutide and Tesamorelin can be viewed together because their current records intersect across Body composition. Their named receptor pathways are currently distinct or incompletely mapped. No controlled human study of the complete combination is represented.

Evidence relationship
Indirect Supporting Evidence

Separate studies or a subset of pairings support related research questions, but they do not establish what the complete combination does.

Research confidence
Moderate

The relationship is supported by indirect human evidence or a published overlap boundary, but full combination outcomes remain unresolved.

Meaningful overlap

Meaningful overlap appears across Body composition.

What current science suggests

Current evidence supports the selected compounds independently across related questions. It cannot determine whether combined effects would be additive, independent, competing, or unrelated.

Biggest unknown

Does studying Retatrutide and Tesamorelin together produce additive, independent, competing, or unrelated effects?

This organizes current research. It is not a recommendation, safety clearance, dosing plan, or prediction of individual outcomes.

Scientific rationale

Why Researchers Study This Combination

Researchers may be interested in this combination because the compounds reach Body composition through different named biological pathways. Whether viewing them together changes measured outcomes remains unresolved unless direct combination evidence is identified above.

Research map

Shared vs. primarily unique

Overlap first, individual focus second
Shared research themes
  • Body composition
Primarily unique to

Retatrutide

Triple receptor agonist
  • Metabolic health
Primarily unique to

Tesamorelin

Growth hormone–releasing hormone (GHRH) analog
  • No clearly unique theme in the current map.

Open research questions

Questions current research cannot yet answer

These questions describe the boundary of the evidence—not missing instructions or predicted outcomes.

  • Does studying Retatrutide and Tesamorelin together produce additive, independent, competing, or unrelated effects?
  • Do the separate findings across Body composition remain independent when the compounds are viewed as one combination?
  • Which populations, exposure durations, formulations, and endpoints would be needed to evaluate the combination fairly?
  • What longer-term outcomes or uncommon effects would only appear in larger controlled research?

Deeper when you want it

Explore the evidence map

Open only the detail you need
Pathways and biological overlapShared targets and what remains unique to each compound
Shared named pathways
  • No duplicate named receptor target is currently mapped. This does not establish compatibility.
RetatrutidePrimarily unique named pathways
  • GLP-1R
  • GIPR
  • GCGR
TesamorelinPrimarily unique named pathways
  • GHRHR
Pair-by-pair evidence relationshipsSee how each selected pair contributes to the full picture
Retatrutide + Tesamorelin
Indirect Supporting Evidence

Separate records intersect across Body composition, but no controlled human study of the combination is represented.

Individual evidence contextStrongest human evidence and biggest unknown by compound
RetatrutideInvestigational
Strongest human evidence
A randomized Phase 3 type 2 diabetes trial was fully published in June 2026; several larger obesity Phase 3 trials also have sponsor-reported topline results.
Biggest unknown
Long-term cardiovascular, renal, and rare-event safety, plus full peer-reviewed reports from the pivotal obesity trials.
Open full compound record
TesamorelinFDA approved for a defined indication
Strongest human evidence
Two randomized Phase 3 trials enrolling 816 adults with HIV-associated abdominal fat accumulation.
Biggest unknown
Long-term cardiovascular safety and whether findings translate beyond the narrow populations studied.
Open full compound record